# FDA requires NAION vision-loss warning across entire GLP-1 drug class

Attorney advertising. Brief by Lou Schwartz, Schwartz & Associates, PC, Atlanta, Georgia. Published 2026-11-09; updated 2026-11-09. Responsible attorney: Lou Schwartz. Canonical: https://www.snalawyers.com/insights/fda-requires-naion-vision-loss-warning-across-entire-glp-1-drug-class

On November 9, 2026, the FDA issued a drug safety communication requiring labeling changes for all GLP-1 receptor agonist medications, including Ozempic, Wegovy, Mounjaro and Zepbound, warning of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a condition that can cause sudden and permanent vision loss in one eye. The agency said its review covered dozens of clinical trials involving more than 130,000 patients and found NAION cases reported for every currently marketed GLP-1 drug. FDA is advising prescribers to consider stopping the drug if NAION is suspected and is asking clinicians to report cases through MedWatch.

**Why it matters.** A class-wide FDA vision-loss warning could support new product-liability claims by GLP-1 users and expand the injury theories at issue alongside existing GLP-1 litigation.

## Sources

1. [UPI](https://www.upi.com/Top_News/US/2026/11/09/fda-warns-glp1ra-meds-risk-of-eye-condition/1111794252185)
2. [Euronews](https://www.euronews.com/2026/11/09/us-drug-watchdog-orders-new-safety-warnings-for-weight-loss-drugs-over-potential-risk-of-v)

To ask the firm about this, use the intake assistant at https://www.snalawyers.com/insights/fda-requires-naion-vision-loss-warning-across-entire-glp-1-drug-class#ask. General information, not legal advice.
